Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Vanda Pharmaceuticals Inc. (VNDA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
14.19+0.28 (+2.01%)
At close: 04:00PM EST
14.19 0.00 (0.00%)
After hours: 04:31PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close13.91
Open13.72
Bid10.00 x 1400
Ask16.16 x 900
Day's Range13.71 - 14.44
52 Week Range13.66 - 21.86
Volume506,463
Avg. Volume473,056
Market Cap790.556M
Beta (5Y Monthly)0.45
PE Ratio (TTM)23.65
EPS (TTM)0.60
Earnings DateFeb 08, 2022 - Feb 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.00
  • GuruFocus.com

    Denali Advisors Llc Buys Sanmina Corp, Mueller Industries Inc, BlueLinx Holdings Inc, Sells , ...

    San Diego, CA, based Investment company Denali Advisors Llc (Current Portfolio) buys Sanmina Corp, Mueller Industries Inc, BlueLinx Holdings Inc, Triton International, World Fuel Services Corp, sells , Adtalem Global Education Inc, Tegna Inc, Federal Agricultural Mortgage Corp, AdvanSix Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Denali Advisors Llc.

  • GuruFocus.com

    Profit Investment Management, LLC Buys Patterson Inc, Vanda Pharmaceuticals Inc, Plantronics ...

    Bethesda, MD, based Investment company Profit Investment Management, LLC (Current Portfolio) buys Patterson Inc, Vanda Pharmaceuticals Inc, Plantronics Inc, American Equity Investment Life Holding Co, PetMed Express Inc, sells , WESCO International Inc, Southwest Airlines Co, Mastercard Inc, NortonLifeLock Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Profit Investment Management, LLC.

  • American City Business Journals

    Vanda Pharmaceuticals settles with generic competitor

    D.C.’s Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has settled a patent infringement lawsuit with a generic competitor over the local company’s key product. Vanda said Friday it has inked a license deal that puts to bed litigation against Piscataway, New Jersey’s MSN Pharmaceuticals Inc. and MSN Laboratories Private Ltd., which wanted to make a generic version of Hetlioz, Vanda’s treatment for non-24-hour sleep-wake disorder. The agreement gives a nonexclusive license to MSN and Impax Laboratories LLC of Hayward, Connecticut (part of Bridgewater, New Jersey’s Amneal Pharmaceuticals LLC), to make and commercialize a product using tasimelteon — the active ingredient in Hetlioz — starting March 13, 2035.

Advertisement
Advertisement